874015--3/1/2010--ISIS_PHARMACEUTICALS

related topics

{product, candidate, development}

{stock, price, share}

{property, intellectual, protect}

{cost, regulation, environmental}

{investment, property, distribution}

{regulation, change, law}

{condition, economic, financial}

{control, financial, internal}

{personnel, key, retain}

{provision, law, control}

{product, market, service}

Risks Associated with our Drug Discovery and Development Business If we or our partners fail to obtain regulatory approval for our drugs, we will not be able to sell them. If the results of clinical testing indicate that any of our drugs under development are not suitable for commercial use we may need to abandon one or more of our drug development programs. Even if our drugs are successful in preclinical and early human clinical studies, these results do not guarantee the drugs will be successful in late-stage clinical trials. If the market does not accept our products, we are not likely to generate revenues or become consistently profitable. If we cannot manufacture our drug products or contract with a third party to manufacture our drug products at costs that allow us to charge competitive prices to buyers, we will not be able to market products profitably. If our drug discovery and development business fails to compete effectively, our drugs will not contribute significant revenues. Disagreements between Alnylam and us regarding the development of our microRNA technology may cause significant delays and other impediments in the development of this technology, which could negatively affect the value of the technology and our investment in Regulus. We depend on third parties in the conduct of our clinical trials for our drugs and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans. Risks Associated with our Businesses as a Whole We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future. Since corporate partnering is a key part of our strategy to fund the development and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our product development programs. Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our product development programs. If we do not progress in our programs as anticipated, the price of our securities could decrease. If we cannot protect our patents or our other proprietary rights, others may compete more effectively against us. Intellectual property litigation could be expensive and prevent us from pursuing our programs. If we fail to obtain timely funding, we may need to curtail or abandon some of our programs. The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success. If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss. Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. If a natural or man-made disaster strikes our research, development or manufacturing facilities, it could delay our progress developing and commercializing our drugs. Provisions in our certificate of incorporation, other agreements and Delaware law may prevent stockholders from receiving a premium for their shares. Future sales of our common stock in the public market could adversely affect the trading price of our securities. Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance. Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.

Full 10-K form ▸

874015--3/1/2010--ISIS_PHARMACEUTICALS_INC